These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34626030)

  • 1. Should we consider broad-spectrum quinolone antibacterial agent as acne treatment in the antimicrobial resistance era?
    Ruffier d'Epenoux L; Guillouzouic A; Bémer P; Dagnelie MA; Khammari A; Dréno B; Corvec S
    J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):e193-e195. PubMed ID: 34626030
    [No Abstract]   [Full Text] [Related]  

  • 2. Relationship between quinolone use and resistance of Staphylococcus epidermidis in patients with acne vulgaris.
    Nakase K; Yoshida A; Saita H; Hayashi N; Nishijima S; Nakaminami H; Noguchi N
    J Dermatol; 2019 Sep; 46(9):782-786. PubMed ID: 31254314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacological profiles and clinical effects of ozenoxacin lotion for the treatments of acne vulgaris and superficial infection of the skin].
    Morimoto H; Kikukawa Y; Murakami N
    Nihon Yakurigaku Zasshi; 2016 Jul; 148(1):39-45. PubMed ID: 27430678
    [No Abstract]   [Full Text] [Related]  

  • 4. Adult acne in women is not associated with a specific type of Cutibacterium acnes.
    Saint-Jean M; Corvec S; Nguyen JM; Le Moigne M; Boisrobert A; Khammari A; Dréno B
    J Am Acad Dermatol; 2019 Sep; 81(3):851-852. PubMed ID: 30905801
    [No Abstract]   [Full Text] [Related]  

  • 5. A profile of Propionibacterium acnes resistance and sensitivity at a tertiary dermatological centre in Singapore.
    Yang SS; Long V; Liau MM; Lee SH; Toh M; Teo J; Tan C; Aw D
    Br J Dermatol; 2018 Jul; 179(1):200-201. PubMed ID: 29368337
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance.
    Leyden JJ; Del Rosso JQ; Webster GF
    Cutis; 2007 Jun; 79(6 Suppl):9-25. PubMed ID: 17649854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [What to think about bacterial resistances in acne?].
    Richet H; Andre-Richet B; Gallou FL
    Ann Dermatol Venereol; 2001 Apr; 128 Supp 1():S15-7; discussion S31-2. PubMed ID: 11450395
    [No Abstract]   [Full Text] [Related]  

  • 8. Antibiotic resistance in the topical treatment of acne vulgaris.
    Leyden JJ
    Cutis; 2004 Jun; 73(6 Suppl):6-10. PubMed ID: 15228128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro Antimicrobial Activity of Acne Drugs Against Skin-Associated Bacteria.
    Blaskovich MAT; Elliott AG; Kavanagh AM; Ramu S; Cooper MA
    Sci Rep; 2019 Oct; 9(1):14658. PubMed ID: 31601845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Novel Topical Cosmeceutical Formulations from
    Nawarathne NW; Wijesekera K; Wijayaratne WMDGB; Napagoda M
    ScientificWorldJournal; 2019; 2019():5985207. PubMed ID: 31485198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metronidazole, its bioactive metabolites and acne.
    Bannatyne RM
    Curr Med Res Opin; 1999; 15(4):298-9. PubMed ID: 10640262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The bacteriology of acne vulgaris and antimicrobial susceptibility of Propionibacterium acnes and Staphylococcus epidermidis isolated from acne lesions.
    Nishijima S; Kurokawa I; Katoh N; Watanabe K
    J Dermatol; 2000 May; 27(5):318-23. PubMed ID: 10875198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct analysis of resistance in the cutaneous microflora during treatment of acne vulgaris with topical 1% nadifloxacin and 2% erythromycin.
    Bojar RA; Hittel N; Cunliffe WJ; Holland KT
    Drugs; 1995; 49 Suppl 2():164-7. PubMed ID: 8549289
    [No Abstract]   [Full Text] [Related]  

  • 14. [Bacteriological studies in acne and the choice of antibiotics for combined therapy].
    Kovalev VM
    Vestn Dermatol Venerol; 1983 Jan; (1):47-50. PubMed ID: 6219510
    [No Abstract]   [Full Text] [Related]  

  • 15. Changes in the management of acne: 2009-2019.
    Thiboutot D; Dréno B; Sanders V; Rueda MJ; Gollnick H
    J Am Acad Dermatol; 2020 May; 82(5):1268-1269. PubMed ID: 32303330
    [No Abstract]   [Full Text] [Related]  

  • 16. Propionibacterium acnes and antimicrobial resistance in acne.
    Dessinioti C; Katsambas A
    Clin Dermatol; 2017; 35(2):163-167. PubMed ID: 28274353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [How long can acne therapeutics be applied?].
    Schnopp C
    Med Monatsschr Pharm; 2006 Sep; 29(9):339-40. PubMed ID: 16984083
    [No Abstract]   [Full Text] [Related]  

  • 18. In vitro antimicrobial susceptibility of Propionibacterium acnes isolated from acne patients in northern Mexico.
    González R; Welsh O; Ocampo J; Hinojosa-Robles RM; Vera-Cabrera L; Delaney ML; Gómez M
    Int J Dermatol; 2010 Sep; 49(9):1003-7. PubMed ID: 20931669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic resistance of microbial strains isolated from Korean acne patients.
    Moon SH; Roh HS; Kim YH; Kim JE; Ko JY; Ro YS
    J Dermatol; 2012 Oct; 39(10):833-7. PubMed ID: 22779738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial susceptibility of Propionibacterium acnes isolates from acne patients in Colombia.
    Mendoza N; Hernandez PO; Tyring SK; Haitz KA; Motta A
    Int J Dermatol; 2013 Jun; 52(6):688-92. PubMed ID: 23451873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.